Upgrade to SI Premium - Free Trial

Biogen (BIIB) Expert Call Highlights Difficulties with Aduhelm Launch, Numbers Need to Come Down - Jefferies

October 13, 2021 9:02 AM
Jefferies analyst Michael Yee reiterated a Buy rating and $400.00 price target on Biogen (NASDAQ: BIIB) after hosting a KOL ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles